Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Otsuka Seeks EU Nod for Lupus Nephritis Drug
Otsuka Pharmaceutical said on June 25 that it has filed an application seeking European regulatory approval for its oral calcineurin inhibitor voclosporin for the treatment of lupus nephritis, a serious complication of systemic lupus erythematosus (SLE). Otsuka inked a license…
To read the full story
Related Article
- Otsuka Gets EU Panel Backing for Lupus Nephritis Drug
July 25, 2022
- Otsuka Gets Japan, European Rights to Aurinia’s Lupus Nephritis Drug
December 18, 2020
BUSINESS
- Halaven Generics Obtain Soft Tissue Sarcoma Use
September 3, 2026
- Ono Teams with Aitia in AI-Driven Neurology Drug Discovery
September 3, 2026
- Nippon Kayaku’s Generic Sunitinib Gains Pancreatic NET Use
September 3, 2026
- GSK Hit with MHLW Guidance over Sponsored Lecture
September 2, 2026
- Nonprescription Cialis Goes Nationwide in Japan, Now at 10,000 Outlets
September 2, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…